Astria Therapeutics Inc (ATXS) Stock
ATXS is no longer traded. Astria Therapeutics was delisted from the Nasdaq in January 2026.
Prices on this page are historical; the last trade was January 21, 2026 at $12.50.
Astria Therapeutics stock price history
ATXS final trading statistics
- Final close
- $12.50
- Final trading day
- Jan 21, 2026
- Market cap at delisting
- $713.56M
- Shares outstanding
- 57.08M
- Final 52-week range
- $3.56 – $13.29
- Avg. volume (final 3 mo.)
- 1,049,495
- All-time high (split-adj.)
- $870.00 · Jul 2015
- All-time low (split-adj.)
- $2.46 · Jun 2022
- Return since IPO
- -98.4%
- Beta
- 0.02
- Book value / share
- $2.44
- Price / book
- 5.11
Astria Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | -$94.3M | -$1.67 |
| FY2023 | $0.00 | -$72.9M | -$2.42 |
| FY2022 | $0.00 | -$50.2M | -$3.63 |
| FY2021 | $0.00 | -$194.9M | -$14.31 |
| FY2020 | $0.00 | -$37.1M | -$12.18 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Astria Therapeutics Inc
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. As of January 23, 2026, Astria Therapeutics, Inc. operates as a subsidiary of BioCryst Pharmaceuticals, Inc.
Astria Therapeutics stock FAQ
What happened to Astria Therapeutics stock?
Astria Therapeutics stock was delisted from the Nasdaq. Its final close was $12.50 on January 21, 2026.
Is ATXS stock still trading?
No. ATXS was delisted from the Nasdaq in January 2026 and no longer trades on a U.S. exchange.
What was the last price of ATXS stock?
ATXS closed at $12.50 on its final trading day, January 21, 2026, for a market value of about $713.56M.
What were Astria Therapeutics's revenue and earnings in its last full fiscal year?
Astria Therapeutics reported revenue of $0.00 and net income of -$94.3M in fiscal 2024, its last full year as a public company.
When did Astria Therapeutics go public?
Astria Therapeutics Inc stock began trading on June 25, 2015.